197 related articles for article (PubMed ID: 31151915)
21. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
Garrido Abad P; Sinués Ojas B; Martínez Blázquez L; Conde Caturla P; Fernández Arjona M
Actas Urol Esp; 2015 Dec; 39(10):635-40. PubMed ID: 26049734
[TBL] [Abstract][Full Text] [Related]
22. Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study.
Kitrey ND; Gruenwald I; Appel B; Shechter A; Massarwa O; Vardi Y
J Urol; 2016 May; 195(5):1550-1555. PubMed ID: 26694904
[TBL] [Abstract][Full Text] [Related]
23. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
Cai Z; Zhang J; Li H
Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
[TBL] [Abstract][Full Text] [Related]
24. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
25. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
[TBL] [Abstract][Full Text] [Related]
26. Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men.
Lee DM; Nazroo J; Pendleton N
Int J Impot Res; 2015 Jul; 27(4):146-51. PubMed ID: 25809698
[TBL] [Abstract][Full Text] [Related]
27. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
28. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation.
Carvalheira AA; Pereira NM; Maroco J; Forjaz V
J Sex Med; 2012 Sep; 9(9):2361-9. PubMed ID: 22616766
[TBL] [Abstract][Full Text] [Related]
29. PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study.
Cairoli C; Reyes LA; Henneges C; Sorsaburu S
Int Braz J Urol; 2014; 40(3):390-9. PubMed ID: 25010306
[TBL] [Abstract][Full Text] [Related]
30. Newer phosphodiesterase inhibitors: comparison with established agents.
McNamara ER; Donatucci CF
Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
[TBL] [Abstract][Full Text] [Related]
31. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial.
Conaglen HM; Conaglen JV
J Sex Med; 2012 Mar; 9(3):857-65. PubMed ID: 22239731
[TBL] [Abstract][Full Text] [Related]
32. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Campbell UB; Walker AM; Gaffney M; Petronis KR; Creanga D; Quinn S; Klein BE; Laties AM; Lewis M; Sharlip ID; Kolitsopoulos F; Klee BJ; Mo J; Reynolds RF
J Sex Med; 2015 Jan; 12(1):139-51. PubMed ID: 25358826
[TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
[TBL] [Abstract][Full Text] [Related]
34. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
[TBL] [Abstract][Full Text] [Related]
35. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of on-demand Elonza; a generic product of sildenafil in Thai men with erectile dysfunction.
Wijitsettakul U; Pempongkosol S
J Med Assoc Thai; 2013 Jun; 96(6):683-8. PubMed ID: 23951825
[TBL] [Abstract][Full Text] [Related]
38. Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
Aversa A; Francomano D; Lenzi A
Expert Opin Pharmacother; 2015 Apr; 16(5):625-8. PubMed ID: 25643866
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
40. [Phosphodiesterase-5 inhibitors for erectile dysfunction: Adverse reactions and countermeasures].
Jiang R; Wu BC
Zhonghua Nan Ke Xue; 2016 Feb; 22(2):99-103. PubMed ID: 26939391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
